endpts.com·Jun 9, 2026
GSK is set to acquire Nuvalent for $10.6 billion to gain access to two experimental lung cancer drugs currently under FDA review, marking one of its largest biotech acquisitions to date.
GSK's acquisition of Nuvalent for $10.6 billion highlights the strategic importance of securing promising cancer drugs that are on the cusp of FDA approval. This move underscores the value placed on advanced-stage biopharma assets with significant potential in precision medicine and oncology, signaling a strong investment opportunity for stakeholders in the biotech and pharmaceutical sectors.